Literature DB >> 11751145

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

Sevtap Arikan1, Mario Lozano-Chiu, Victor Paetznick, John H Rex.   

Abstract

We investigated the in vitro interaction of caspofungin and amphotericin B for clinical isolates of Aspergillus and FUSARIUM: Synergy tests were performed using the checkerboard method and following the NCCLS M38-P guidelines in Antibiotic Medium 3 broth supplemented to 2% glucose. Antagonism was not observed for any of the isolates tested. Caspofungin and amphotericin B were synergistic or synergistic to additive for at least half of the isolates.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11751145      PMCID： PMC127002          DOI： 10.1128/AAC.46.1.245-247.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

Authors:  J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

2.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  Detection of amphotericin B-resistant Candida isolates in a broth-based system.

Authors:  J H Rex; C R Cooper; W G Merz; J N Galgiani; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

4.  Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.

Authors:  G K Abruzzo; C J Gill; A M Flattery; L Kong; C Leighton; J G Smith; V B Pikounis; K Bartizal; H Rosen
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; S Nangia; J H Rex
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

6.  Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.

Authors:  B A Arthington-Skaggs; D W Warnock; C J Morrison
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

7.  Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.

Authors:  S P Franzot; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

8.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Authors:  M B Kurtz; I B Heath; J Marrinan; S Dreikorn; J Onishi; C Douglas
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191
  9 in total
  68 in total

1.  In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.

Authors:  Niki I Paphitou; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae.

Authors:  Sarit Markovich; Aya Yekutiel; Itamar Shalit; Yona Shadkchan; Nir Osherov
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 4.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 5.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 6.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maria J Buitrago; Emilia Mellado; Guillermo Garcia-Effron; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex.

Authors:  Mónica Azor; Josepa Gené; Josep Cano; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

9.  Metabolism and resistance of Fusarium spp. to the manzamine alkaloids via a putative retro pictet-spengler reaction and utility of the rational design of antimalarial and antifungal agents.

Authors:  Noer Kasanah; Lorelei Lucas Farr; Abbas Gholipour; David E Wedge; Mark T Hamann
Journal:  Mar Biotechnol (NY)       Date:  2014-02-20       Impact factor: 3.619

10.  Sequential therapy with caspofungin and fluconazole for Candida albicans infection.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Isabella Baldassarri; Anna Marigliano; Daniela Arzeni; Daniele Giannini; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.